TEST BANK |
INTRODUCTORY CLINICAL PHARMACOLOGY 12TH EDITION
| | | |
by Susan M Ford
| | |
, Chapter 01: General Principles of Pharmacology
| | | | |
Ford: Introductory Clinical Pharmacology 12th Edition
| | | | |
1. After|teaching|a|group|of |students|about|the|basics |of|pharmacology, |the|students |will |be |able |to
|choose |which |aspect |as |the |most |critical |to |remember?
A) Drug |name
B) Drug |class
C) Drug |action
D) Drug |source
Answer: |C
Rationale: |Pharmacology |is |the |study |of |drugs |and |its |action |on |living |organisms. |Thus, |an
|essential |aspect |of |pharmacology |is |drug |action. |An |understanding |of |the |drug |name, |drug
|class, |and |drug |source |is |important, |but |the |most |critical |aspect |related |to |pharmacology |is |how
|the |drug |acts |in |the |body.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |1
|Cognitive |Level: |Apply
Client |Needs: |Physiological |Integrity: |Pharmacological |Therapies
|Integrated |Process: |Teaching/Learning
Reference: |p. |3, |Introduction
2. A |nurse |suspects |the |client |had |an |adverse |reaction |to |a |prescribed |medication |due |to |an
|interaction |with |an |unreported |over-the-counter |supplement. |Which |action |by |the |nurse
|will |best |assist |in |preventing |future |similar |incidents?
A) File |a |report |with |MedWatch
B) File |a |report |with |the |State |Board |of |Nursing
C) Instruct |the |client |to |avoid |combining |medications |in |the |future
D) Document |the |incident |and |report |it |to |the |health |care |provider
Answer: |A
Rationale: |Nurses |play |an |important |role |in |monitoring |for |adverse |reactions. |Therefore, |it |is
|important |to |submit |reports, |even |if |there |is |uncertainty |about |the |cause–effect |relationship.
|The |FDA |protects |the |identity |of |those |who |voluntarily |report |adverse |reactions.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |9
|Cognitive |Level: |Apply
, Client |Needs: |Safe |and |Effective |Care |Environment: |Safety |and |InfectionControl
Integrated |Process: |Clinical |Problem-solving |Process |(Nursing |Process)
|Reference: |p. |7, |Box |1.1 |MedWatch |and |Reporting |Adverse |Events
3. A |nurse |is |assessing |a |client |and |notes |the |client |has |developed |swelling |of |the |eyelids |and
|lips |after |administration |of |a |prescribed |medication. |What |does |the |nurse |interpret |this
|finding |to |specifically |indicate?
A) Mild |allergic |reaction
B) Anaphylactic |shock
C) Angioedema
D) Drug |idiosyncrasy
Answer: |C
Rationale: |Angioedema |is |a |type |of |allergic |drug |reaction |manifested |by |the |collection |of |fluid
|in |the |subcutaneous |tissues, |most |commonly |affecting |the |eyelids, |lips, |mouth, |and |throat.
|Allergic |reactions |can |be |manifested |by |a |wide |range |of |signs |and |symptoms |such |as |itching,
|rashes, |and |hives. |Anaphylactic |shock |is |a |serious |allergic |reaction |that |requires |immediate
|medical |attention. |Drug |idiosyncrasydescribes |anyunusual |or |abnormal |reaction |to |a |drug, |one
|that |is |different |from |the |one |normally |expected.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |5
|Cognitive |Level: |Apply
Client |Needs: |Physiological |Integrity: |Reduction |of |Risk |Potential |Integrated
|Process: |Clinical |Problem-solving |Process |(Nursing |Process) |Reference: |p. |12,
|Allergic |Drug |Reactions
4. The |nurse |is |preparing |to |teach |a |client |about |a |new |drug |which |is |in |the |fourth |phase |of
|development. |Which |activity |will |the |nurse |explain |best |illustrates |this |phase?
A) Health |care |providers |report |adverse |effects |to |FDA.
B) Healthy |volunteers |are |involved |in |the|test.
C) In |vitro |tests |are |performed |using |human |cells.
D) The |drug |is |given |to |clients |with |the|disease.
Answer: |A
, Rationale: |The |postmarketing |surveillance |phase |of |drug |development |encourages |health |care
|professionals |to |report |adverse |effects |of |drugs |to |the |FDA | using |MedWatch. |Phase |1 |of |clinical
|testing |involves |20 |to |100 |healthy |volunteers. |In |vitro |testing |of |the |drug |on |human |or |animal
|cells |is |done |in |the |pre-FDA |phase. | In |Phase |2 |of |clinical |testing, |the |drug |is |given |to |clients |with |the
|disease |for |which |the |drug |is |manufactured.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |4
|Cognitive |Level: |Apply
Client |Needs: |Health |Promotion |and |Maintenance
|Integrated |Process: |Teaching/Learning |Reference: |p. |7,
|Concept |Mastery |Alert
5. A |nurse |is |assessing |a |pregnant |client |who |admits |to |having |a |cocaine |addiction. |Which
|condition |of |the |baby |after |birth |should |the |nurse |explain |and |preparethe |client |for?
A) Diabetes
B) Hypertension
C) Addiction |to |drugs
D) CNS |defects
Answer: |C
Rationale: |The |nurse |informs |the |client |that |children |born |to |mothers |using |addictive |drugs
|are |often |born |with |an |addiction |to |the |drug. |Children |born |to |mothers |who |are |addicted |to
|cocaine |are |not |known |to |be |born |with |diabetes, |CNS |defects, |or |hypertension.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |6
|Cognitive |Level: |Apply
Client |Needs: |Health |Promotion |and |Maintenance
|Integrated |Process: |Teaching/Learning
Reference: |p. |11, |Drug |Use, |Pregnancy, |and |Lactation
6. A |client |arrives |at |the |health |care |clinic |and |reports |taking |several |pills |for |a |headacheand
|severe |cough |without |relief. |Which |adverse |effect |should |the |nurse |be |aware |may |develop
|from |this |combination?
A) Gastrointestinal |bleeding
B) Breathing |difficulties
C) Liver |damage
D) Anaphylaxis
INTRODUCTORY CLINICAL PHARMACOLOGY 12TH EDITION
| | | |
by Susan M Ford
| | |
, Chapter 01: General Principles of Pharmacology
| | | | |
Ford: Introductory Clinical Pharmacology 12th Edition
| | | | |
1. After|teaching|a|group|of |students|about|the|basics |of|pharmacology, |the|students |will |be |able |to
|choose |which |aspect |as |the |most |critical |to |remember?
A) Drug |name
B) Drug |class
C) Drug |action
D) Drug |source
Answer: |C
Rationale: |Pharmacology |is |the |study |of |drugs |and |its |action |on |living |organisms. |Thus, |an
|essential |aspect |of |pharmacology |is |drug |action. |An |understanding |of |the |drug |name, |drug
|class, |and |drug |source |is |important, |but |the |most |critical |aspect |related |to |pharmacology |is |how
|the |drug |acts |in |the |body.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |1
|Cognitive |Level: |Apply
Client |Needs: |Physiological |Integrity: |Pharmacological |Therapies
|Integrated |Process: |Teaching/Learning
Reference: |p. |3, |Introduction
2. A |nurse |suspects |the |client |had |an |adverse |reaction |to |a |prescribed |medication |due |to |an
|interaction |with |an |unreported |over-the-counter |supplement. |Which |action |by |the |nurse
|will |best |assist |in |preventing |future |similar |incidents?
A) File |a |report |with |MedWatch
B) File |a |report |with |the |State |Board |of |Nursing
C) Instruct |the |client |to |avoid |combining |medications |in |the |future
D) Document |the |incident |and |report |it |to |the |health |care |provider
Answer: |A
Rationale: |Nurses |play |an |important |role |in |monitoring |for |adverse |reactions. |Therefore, |it |is
|important |to |submit |reports, |even |if |there |is |uncertainty |about |the |cause–effect |relationship.
|The |FDA |protects |the |identity |of |those |who |voluntarily |report |adverse |reactions.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |9
|Cognitive |Level: |Apply
, Client |Needs: |Safe |and |Effective |Care |Environment: |Safety |and |InfectionControl
Integrated |Process: |Clinical |Problem-solving |Process |(Nursing |Process)
|Reference: |p. |7, |Box |1.1 |MedWatch |and |Reporting |Adverse |Events
3. A |nurse |is |assessing |a |client |and |notes |the |client |has |developed |swelling |of |the |eyelids |and
|lips |after |administration |of |a |prescribed |medication. |What |does |the |nurse |interpret |this
|finding |to |specifically |indicate?
A) Mild |allergic |reaction
B) Anaphylactic |shock
C) Angioedema
D) Drug |idiosyncrasy
Answer: |C
Rationale: |Angioedema |is |a |type |of |allergic |drug |reaction |manifested |by |the |collection |of |fluid
|in |the |subcutaneous |tissues, |most |commonly |affecting |the |eyelids, |lips, |mouth, |and |throat.
|Allergic |reactions |can |be |manifested |by |a |wide |range |of |signs |and |symptoms |such |as |itching,
|rashes, |and |hives. |Anaphylactic |shock |is |a |serious |allergic |reaction |that |requires |immediate
|medical |attention. |Drug |idiosyncrasydescribes |anyunusual |or |abnormal |reaction |to |a |drug, |one
|that |is |different |from |the |one |normally |expected.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |5
|Cognitive |Level: |Apply
Client |Needs: |Physiological |Integrity: |Reduction |of |Risk |Potential |Integrated
|Process: |Clinical |Problem-solving |Process |(Nursing |Process) |Reference: |p. |12,
|Allergic |Drug |Reactions
4. The |nurse |is |preparing |to |teach |a |client |about |a |new |drug |which |is |in |the |fourth |phase |of
|development. |Which |activity |will |the |nurse |explain |best |illustrates |this |phase?
A) Health |care |providers |report |adverse |effects |to |FDA.
B) Healthy |volunteers |are |involved |in |the|test.
C) In |vitro |tests |are |performed |using |human |cells.
D) The |drug |is |given |to |clients |with |the|disease.
Answer: |A
, Rationale: |The |postmarketing |surveillance |phase |of |drug |development |encourages |health |care
|professionals |to |report |adverse |effects |of |drugs |to |the |FDA | using |MedWatch. |Phase |1 |of |clinical
|testing |involves |20 |to |100 |healthy |volunteers. |In |vitro |testing |of |the |drug |on |human |or |animal
|cells |is |done |in |the |pre-FDA |phase. | In |Phase |2 |of |clinical |testing, |the |drug |is |given |to |clients |with |the
|disease |for |which |the |drug |is |manufactured.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |4
|Cognitive |Level: |Apply
Client |Needs: |Health |Promotion |and |Maintenance
|Integrated |Process: |Teaching/Learning |Reference: |p. |7,
|Concept |Mastery |Alert
5. A |nurse |is |assessing |a |pregnant |client |who |admits |to |having |a |cocaine |addiction. |Which
|condition |of |the |baby |after |birth |should |the |nurse |explain |and |preparethe |client |for?
A) Diabetes
B) Hypertension
C) Addiction |to |drugs
D) CNS |defects
Answer: |C
Rationale: |The |nurse |informs |the |client |that |children |born |to |mothers |using |addictive |drugs
|are |often |born |with |an |addiction |to |the |drug. |Children |born |to |mothers |who |are |addicted |to
|cocaine |are |not |known |to |be |born |with |diabetes, |CNS |defects, |or |hypertension.
Question |Format: |Multiple |Choice
|Chapter: |1
Learning |Objective: |6
|Cognitive |Level: |Apply
Client |Needs: |Health |Promotion |and |Maintenance
|Integrated |Process: |Teaching/Learning
Reference: |p. |11, |Drug |Use, |Pregnancy, |and |Lactation
6. A |client |arrives |at |the |health |care |clinic |and |reports |taking |several |pills |for |a |headacheand
|severe |cough |without |relief. |Which |adverse |effect |should |the |nurse |be |aware |may |develop
|from |this |combination?
A) Gastrointestinal |bleeding
B) Breathing |difficulties
C) Liver |damage
D) Anaphylaxis
